Evidence map›Paper›PMID 26722379›Full record

ArticleTheranostics2016

NIR-Cyanine Dye Linker: a Promising Candidate for Isochronic Fluorescence Imaging in Molecular Cancer Diagnostics and Therapy Monitoring.

Dorde Komljenovic, Manfred Wiessler, Waldemar Waldeck, Volker Ehemann, Ruediger Pipkorn, Hans-Hermann Schrenk, Jürgen Debus, Klaus Braun

Abstract read
In one paragraph

Article in Theranostics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Pre-clinical study of IR808 dye for cervical cancer in vitro and in vivo imaging.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Molecules (Basel, Switzerland) · 2023
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dorde Komljenovic1. German Cancer Research Center, Department of Medical Physics in Radiology, INF 280, 69120 Heidelberg, Germany.
Manfred Wiessler1. German Cancer Research Center, Department of Medical Physics in Radiology, INF 280, 69120 Heidelberg, Germany.
Waldemar Waldeck2. German Cancer Research Center, Division of Biophysics of Macromolecules, INF 580, 69120 Heidelberg, Germany.
Volker Ehemann3. University of Heidelberg, Institute of Pathology, INF 224, 69120 Heidelberg, Germany.
Ruediger Pipkorn4. German Cancer Research Center, Department of Translational Immunology, INF 580, 69120 Heidelberg, Germany.
Hans-Hermann Schrenk1. German Cancer Research Center, Department of Medical Physics in Radiology, INF 280, 69120 Heidelberg, Germany.
Jürgen Debus5. University of Heidelberg, Department of Radiation Oncology, INF 400, 69120 Heidelberg, Germany.
Klaus Braun1. German Cancer Research Center, Department of Medical Physics in Radiology, INF 280, 69120 Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Personalized anti-cancer medicine is boosted by the recent development of molecular diagnostics and molecularly targeted drugs requiring rapid and efficient ligation routes. Here, we present a novel approach to synthetize a conjugate able to act simultaneously as an imaging and as a chemotherapeutic agent by coupling functional peptides employing solid phase peptide synthesis technologies. Development and the first synthesis of a fluorescent dye with similarity in the polymethine part of the Cy7 molecule whose indolenine-N residues were substituted with a propylene linker are described. Methylating agent temozolomide is functionalized with a tetrazine as a diene component whereas Cy7-cell penetrating peptide conjugate acts as a dienophilic reaction partner for the inverse Diels-Alder click chemistry-mediated ligation route yielding a theranostic conjugate, 3-mercapto-propionic-cyclohexenyl-Cy7-bis-temozolomide-bromide-cell penetrating peptide. Synthesis route described here may facilitate targeted delivery of the therapeutic compound to achieve sufficient local concentrations at the target site or tissue. Its versatility allows a choice of adequate imaging tags applicable in e.g. PET, SPECT, CT, near-infrared imaging, and therapeutic substances including cytotoxic agents. Imaging tags and therapeutics may be simultaneously bound to the conjugate applying click chemistry. Theranostic compound presented here offers a solid basis for a further improvement of cancer management in a precise, patient-specific manner.

Indexed as

AnimalsAntineoplastic AgentsCell Line, TumorFluorescent DyesMolecular Diagnostic TechniquesMolecular Targeted TherapyNeoplasmsOptical ImagingPrecision MedicineRatsAntineoplastic AgentsFluorescent DyesClick chemistryfluorescent dyeinverse Diels-Alder reactionmolecular diagnosticsmultimodal imagingnear infrared imagingsolid phase peptide synthesis.

Identifiers

PMID26722379
PMCPMC4679360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.